Altre lingue Brii Biosciences Limited

Azioni

2137

KYG1645A1094

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:09:13 23/04/2024			Variaz. 5gg	Var. 1 gen.
0,98 ^HKD	-2,97%		+5,38%	-57,02%

25/03	Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
22/03	Brii Biosciences Limited riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	05/03
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	14/02
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	14/02
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	14/02
Brii Biosciences Hires Chief Scientific Officer	04/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference	14/11
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B	07/09/23
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability	06/09/23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	06/09/23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	06/09/23
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	06/09/23
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results	22/08/23
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	31/07/23
Brii Biosciences Collaborates with VBI Vaccines for Hepatitis B Project	06/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Brii Biosciences Limited

Azioni

2137

KYG1645A1094

Altre lingue

Filtri